This emergent canonical NF-κB activity has consequences: it reduced the efficacy of the MEK inhibitor trametinib in RAP tumours at least in part by increasing glucuronidation of the drug (Fig. 8D). This evidence concerns the gene NFKB1 and neoplasm.